Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

INTRODUCTION: Advanced non-small cell lung cancer (NSCLC) is still a therapeutic challenge as the 5-year survival is under 30%. The optimal treatment regimen is still under debate. HYPOTHESIS: Neo adjuvant (NA) treatment given pre-pneumonectomy does not increase surgical complexity or peri-OP mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dan, Aravot, Yaron, Barac D., Efrat, Krutzwald-Josefson, Allen Aaron, M., Dov, Flex, Nir, Peled, Kramer Mordechai, R., Yuri, Peysakhovich, Milton, Saute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327573/
https://www.ncbi.nlm.nih.gov/pubmed/30626407
http://dx.doi.org/10.1186/s13019-018-0829-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327573/
https://www.ncbi.nlm.nih.gov/pubmed/30626407
http://dx.doi.org/10.1186/s13019-018-0829-z

Ejemplares similares